Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma.

These ex vivo results would provide a biological basis to data available from studies showing a clinical benefit with the use of G-CSF as a priming agent in patients with a chemosensitive AML and would support implementation of further studies exploring new strategies of chemotherapy priming in AML.